Download Files:
Products Details
Product Description
– Zafirlukast-13C,d3 is the 13C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
Web ID
– HY-17492S1
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C30 13CH30D3N3O6S
References
– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.|[2]Finnerty JP, et al. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D<sub>4</sub> receptor antagonist. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):746-9.|[3]Gunning WT, et al. Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res. 2002 Aug 1;62(15):4199-201.|[4]Lei C, et al. Zafirlukast attenuates advanced glycation end-products (AGEs)-induced degradation of articular extracellular matrix (ECM). Int Immunopharmacol. 2019;68:68-73.
Molecular Weight
– 579.69
SMILES
– O=C(NC1=CC(C(CC2=CC=C(C(NS(=O)(C3=C(C)C=CC=C3)=O)=O)C=C2O[13C]([2H])([2H])[2H])=CN4C)=C4C=C1)OC5CCCC5
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology; Cancer
Solubility
– 10 mM in DMSO
Target
– Isotope-Labeled Compounds;Leukotriene Receptor
Pathway
– GPCR/G Protein;Others
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
